Intervention
Taselisib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownTesting GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)NCT04439175 · 2016-02-25
ACTIVE_NOT_RECRUITINGTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITINGTaselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerNCT02457910 · 2015-06-01
TERMINATEDPhase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast CancerNCT02390427 · 2015-04-20
COMPLETEDA Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor TherapyNCT02340221 · 2015-04-09
TERMINATEDA Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)NCT02273973 · 2014-11-12
COMPLETEDLung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesNCT02785913 · 2014-11-01
COMPLETEDLung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung CancerNCT02154490 · 2014-07-08
COMPLETEDCommon conditions
Advanced Lymphoma2Advanced Malignant Solid Neoplasm2Breast Cancer2Hematopoietic and Lymphoid Cell Neoplasm2Recurrent Squamous Cell Lung Carcinoma2Refractory Lymphoma2Refractory Malignant Solid Neoplasm2Refractory Multiple Myeloma2Bladder Carcinoma1Breast Carcinoma1Cervical Carcinoma1Colon Carcinoma1Colorectal Carcinoma1Endometrial Carcinoma1Esophageal Carcinoma1Estrogen Receptor Negative1Estrogen Receptor Positive1Exocrine Pancreas Carcinoma1Gastric Carcinoma1Glioma1Head and Neck Carcinoma1HER2/Neu Negative1Kidney Carcinoma1Liver Carcinoma1Lung Carcinoma1
Leading sponsors
Trial status mix
COMPLETED4
ACTIVE_NOT_RECRUITING2
TERMINATED2
Phase mix
PHASE25
PHASE12
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.